This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the knee.
Journal: Journal of Rheumatology
Authors: Day R, Brooks P, Conaghan PG, Peterson M, on behalf of the Multicenter Trial Group.
Intraarticular HA† treatment was significantly more effective than saline vehicle in mild to moderate OA* of the knee for the 13-week post injection period of the study.
An integrated analysis of five double-blind, randomized controlled trials evaluating the safety and efficacy of a hyaluronan product for intra-articular injection in osteoarthritis of the knee.
Journal: Osteoarthritis and Cartilage
Authors: Strand V, Conaghan PG, Lohmander LS, Koutsoukos AD, Hurley FL, Bird H, Brooks P, Day R, Puhl W, Band PA.
Analysis of over 1,100 patients demonstrated SUPARTZ FX to be effective in treating knee OA* pain with a safety profile similar to placebo.
Hyaluronate improves pain, physical function and balance in the geriatric osteoarthritic knee: a 6-month follow-up study using clinical tests.
Journal: Osteoarthritis and Cartilage
Authors: Sun SF, Hsu CW, Hwang CW, Hsu PT, Wang JL, Tsai SL, Chou YJ, Hsu YW, Huang CM, Wang YL.
Significant improvement in pain, physical function and balance tests was demonstrated after five weekly SUPARTZ FX injections in geriatric patients with knee OA*. The effect had rapid onset at 1 week and may last for 6 months.